Proviron Side Effects: The Complete Dose-Specific Risk Profile That Separates Clinical Data From Forum Myths

Every Proviron side effects article online falls into one of two traps. Either it minimises everything (“Proviron is one of the safest steroids, virtually no side effects”) or it copies a generic list of steroid side effects that apply to compounds nothing like mesterolone (“liver damage, cardiovascular collapse, roid rage”). Neither approach helps you. What you need is a dose-specific, mechanism-based breakdown that tells you which side effects are real at your dose, which are genetic, which are universal, and which are myths that come from confusing Proviron with 17-alpha-alkylated oral steroids it shares almost nothing in common with. That is what this article provides. Hemi Pharma UK supplies pharmaceutical-grade mesterolone in a 25mg tablet format, and accurate side effect information is part of the responsibility that comes with making a verified product available.

What Does the Manufacturer’s Official Safety Data Actually List?

The Bayer Summary of Product Characteristics (SmPC), updated November 2023, is the regulatory document that defines the known adverse reaction profile of mesterolone based on spontaneous reporting and published scientific literature. The listed adverse reactions, all classified as “frequency unknown” because they come from post-marketing surveillance rather than controlled trials with calculable incidence rates, are: acne (skin and subcutaneous tissue disorders), headache (nervous system disorders), increased number of erections and priapism (reproductive system and breast disorders) (Bayer Proviron SmPC, Section 4.8, November 2023).

That is the complete official list. Four adverse reactions. No liver toxicity. No cardiovascular events. No psychiatric disorders. No haematological changes. Compare this to the adverse reaction section of any 17-alpha-alkylated oral steroid (such as oxymetholone or stanozolol) and the contrast is stark. This does not mean mesterolone is without risk. It means the regulatory-grade evidence base for serious adverse events is thin, which itself is a data point: a drug prescribed continuously since 1967 that has generated only four adverse reaction categories in post-marketing surveillance over nearly 60 years has a genuinely mild safety profile.

Is Liver Toxicity a Real Proviron Side Effect?

No. This is the single most important distinction between mesterolone and most other oral androgens, and it is the side effect most frequently misattributed to Proviron by people who do not understand the structural chemistry. Hepatotoxicity in oral steroids is caused by 17-alpha-alkylation: the addition of a methyl or ethyl group at the C-17-alpha position, which protects the steroid from hepatic first-pass destruction but in doing so forces the liver to process a structurally resistant molecule that causes cholestatic injury, peliosis hepatis, and elevated transaminases.

Mesterolone does not carry 17-alpha-alkylation. It uses 1-alpha-methylation, a completely different structural modification at a different carbon position. This modification provides enough metabolic resistance for oral absorption (approximately 3% bioavailability) without creating the bile duct obstruction and hepatocyte damage that 17-alpha-alkylation produces. The Bayer SmPC confirms this implicitly by not listing any hepatic adverse reactions. The Kicman (2008) review in British Journal of Pharmacology explicitly classified mesterolone among the non-hepatotoxic oral androgens (Br J Pharmacol, 154(3), 502-521). If your Proviron side effects source lists “liver damage,” that source has confused mesterolone with a different class of compound.

Does Proviron Cause Hair Loss and How Much Depends on Your Genetics?

Hair loss is a real androgenic side effect of mesterolone, but its magnitude is widely overstated because people hear “DHT derivative” and assume maximum follicular damage. The actual risk depends on three factors: your genetic predisposition to androgenetic alopecia, the dose you are using, and the pharmacokinetic limitations of the compound.

Mesterolone is already 5-alpha-reduced. It cannot be amplified by 5-alpha-reductase at the hair follicle the way testosterone can. Its oral bioavailability is approximately 3%, meaning roughly 0.75mg of a 25mg tablet reaches systemic circulation. Of that, 98% is bound to serum proteins (58% SHBG, 40% albumin), leaving approximately 2% in the free fraction available to enter tissue. And in skin, mesterolone is further degraded by 3-alpha-HSD. The cumulative result is that the androgenic load mesterolone delivers to scalp follicles is a fraction of what endogenous DHT conversion from testosterone produces in a man on TRT.

At 25mg daily, hair loss acceleration is minimal in all but the most genetically susceptible men. At 50mg daily, some predisposed men may notice increased shedding. At 75 to 100mg daily, the risk rises proportionally but remains lower than what injectable DHT derivatives like drostanolone (Masteron) produce at standard doses. Men without genetic predisposition to androgenetic alopecia can use mesterolone at clinical doses indefinitely without hair loss, because the androgen receptor density in their follicles does not produce the miniaturisation cascade regardless of DHT exposure.

What Does Proviron Actually Do to Your Lipids?

This is an area where human clinical data and preclinical animal data diverge, and understanding both is necessary for an honest assessment. In humans, Nikkanen (1979) treated 24 healthy men with mesterolone at 75mg daily for six months and found no significant changes in plasma cholesterol or triglycerides (Andrologia, 11(1), 33-36). This is the most commonly cited lipid safety data for Proviron, and it is reassuring at clinical doses.

However, Casquero, Casquero, Martins, Braga de Oliveira, Cotrim, Joviliano, Fernandes and Oliveira (2008) studied mesterolone’s effects on lipoprotein profiles in transgenic mice that express human cholesteryl ester transfer protein (CETP), a model that more closely mimics human lipoprotein metabolism than wild-type mice. They found that mesterolone treatment increased total cholesterol, triglycerides, LDL cholesterol, and VLDL cholesterol in sedentary mice. Importantly, exercise training attenuated these effects by increasing HDL cholesterol and decreasing LDL and VLDL (Clinical and Experimental Pharmacology and Physiology, 36(1), 2009).

The practical interpretation is that mesterolone at clinical doses in active men (which describes the majority of Proviron users) is unlikely to produce clinically significant lipid disturbance, consistent with the Nikkanen human data. In sedentary individuals or at higher doses, lipid monitoring becomes more important. Regardless of dose, running a lipid panel before starting Proviron and at 8-to-12-week intervals is sound practice. The key takeaway is that mesterolone is substantially milder on lipids than 17-alpha-alkylated oral steroids (stanozolol can reduce HDL by 30 to 50% at standard doses), but it is not completely lipid-neutral at all doses in all populations.

Does Proviron Suppress Natural Testosterone Production?

Yes, but the degree of suppression is categorically different from other androgens. Wang et al. (1974) documented a 19% LH decline and 21% FSH decline at 100mg daily, and a 15% LH decline and 18% FSH decline at 200mg daily (Andrologia, 6(2), 111-118). Compare this to nandrolone, trenbolone, or even oral testosterone derivatives, which suppress gonadotropins to undetectable levels within days.

At TRT doses of 25 to 50mg daily, where the user’s HPG axis is already suppressed by exogenous testosterone, Proviron’s mild suppressive effect is clinically irrelevant. Where it matters is in two contexts: men using Proviron as a standalone compound (where even 15-20% suppression adds to whatever baseline suppression they have), and during PCT, where any additional negative feedback works against the goal of HPG axis recovery.

Does Proviron Affect the Prostate?

All androgens can stimulate prostatic tissue. Mesterolone is no exception. The Bayer SmPC states under Section 4.4 (Special Warnings and Precautions): “Regular examinations of the prostate should be carried out as precaution measures.” This is a blanket recommendation for all androgen therapies, not a specific warning unique to mesterolone.

The nuance is that mesterolone, unlike testosterone, cannot be amplified by 5-alpha-reductase in the prostate (it is already 5-alpha-reduced). Testosterone’s prostatic risk comes partly from local DHT production within prostate tissue, where 5-alpha-reductase type II converts testosterone to the more potent DHT. Mesterolone arrives at the prostate as itself, without local amplification. The prostatic androgenic load from 50mg of oral mesterolone (of which 1.5mg reaches circulation) is substantially lower than the prostatic DHT produced from a 200mg weekly testosterone injection.

PSA monitoring is nonetheless recommended. Baseline PSA before starting Proviron, then at 12-week intervals during use. Any significant PSA elevation (greater than 1.4 ng/mL increase from baseline, or any single reading above 4.0 ng/mL) warrants investigation and potential discontinuation, as with any androgen therapy.

Can Proviron Cause Acne?

Acne is listed in the Bayer SmPC as a known adverse reaction. The mechanism is straightforward: mesterolone is an androgen, and androgens stimulate sebaceous gland activity, increasing sebum production. Excess sebum can clog pores and trigger inflammatory acne, particularly in individuals with pre-existing acne-prone skin or high sebaceous gland density.

At 25mg daily, acne incidence is low. At 50mg daily, some acne-prone individuals report mild breakouts. At 75 to 100mg daily, acne becomes more likely in susceptible individuals. The severity is typically mild to moderate (increased oiliness, scattered papules) rather than the severe cystic acne that high-dose testosterone or trenbolone can produce. Men who do not normally experience acne on TRT are unlikely to develop it by adding 25 to 50mg of Proviron.

Does Proviron Cause Mood Changes, Aggression, or Anxiety?

This is the area with the widest gap between clinical evidence and forum reports. The Bayer SmPC does not list any psychiatric adverse reactions. The Vogel et al. (1985) study found that mesterolone had antidepressant effects equivalent to amitriptyline in 34 depressed men, with fewer side effects (J Clin Psychiatry, 46(1), 6-8). The clinical evidence base points toward mood improvement, not deterioration.

However, forum reports of anxiety and irritability on Proviron are not fabricated. The likely explanation is the androgen-to-oestrogen ratio. When Proviron shifts this ratio too far toward the androgenic side, particularly in men who already have low oestrogen or are simultaneously using an aromatase inhibitor like anastrozole, the resulting oestrogen deficit produces symptoms that include anxiety, irritability, flat mood, and insomnia. The man attributes these symptoms to Proviron as a “side effect,” when in reality the cause is the downstream oestrogen suppression created by the ratio shift. Reducing the Proviron dose or reducing the AI dose typically resolves the issue. This is not a direct pharmacological side effect of mesterolone. It is an indirect consequence of overdoing the androgen-to-oestrogen ratio shift.

Does Proviron Affect Haematocrit or Red Blood Cell Count?

Erythrocytosis (elevated haematocrit and red blood cell count) is a well-documented side effect of testosterone replacement therapy. It occurs because androgens stimulate erythropoietin production in the kidneys, increasing red blood cell synthesis. The Bayer SmPC for Proviron does not list haematological adverse reactions, and the clinical literature does not report significant haematocrit elevation with mesterolone at standard doses.

This is consistent with the compound’s pharmacokinetics: the 3% bioavailability limits systemic androgenic exposure to levels unlikely to drive clinically significant erythropoiesis. Men on TRT who are already monitoring haematocrit should continue doing so after adding Proviron, but the additional contribution of mesterolone to haematocrit elevation is expected to be negligible compared to the testosterone base.

What Side Effects Should You Monitor at Each Dose?

At 25mg daily: minimal monitoring beyond standard TRT bloodwork. Hair shedding unlikely unless strongly predisposed. Acne unlikely. Lipids unaffected. Mood typically improved. At 50mg daily: monitor for mild hair shedding in predisposed men. Acne possible in acne-prone individuals. Lipid panel at 12 weeks. PSA at 12 weeks. Check free testosterone and SHBG to confirm dose is producing desired effect. At 75mg daily: all of the above, with slightly increased vigilance for androgenic effects. This is the dose most frequently used in clinical trials, and the Nikkanen data confirms lipid neutrality at this level in healthy active men. At 100mg daily: the upper boundary of standard dosing. Androgenic side effects (hair, acne, prostate stimulation) are dose-dependent and more likely. Lipid monitoring essential. PSA monitoring essential. Cost-to-benefit analysis should justify this dose over lower alternatives.

What Proviron Side Effects Are Myths?

Liver damage: myth. Mesterolone is not 17-alpha-alkylated and does not cause hepatotoxicity. Water retention: myth. Mesterolone does not aromatise and cannot cause oestrogen-mediated fluid retention. Gynecomastia: myth. Mesterolone cannot convert to oestrogen. If anything, it provides anti-oestrogenic ratio shifting that reduces gynecomastia risk. Massive testosterone suppression: myth at clinical doses. Suppression exists but is 15-21%, not the near-total suppression seen with other androgens. Kidney damage: no evidence. Not listed in the SmPC, not reported in clinical literature. “Roid rage”: no evidence. The clinical data (Vogel 1985) shows antidepressant effects, not aggression promotion.

Frequently Asked Questions

What are the most common Proviron side effects?

According to the Bayer SmPC (November 2023), the listed adverse reactions are acne, headache, increased number of erections, and priapism. All are classified as “frequency unknown” from post-marketing surveillance. At clinical doses of 25 to 50mg daily, the majority of users report no adverse effects. Acne and increased libido are the most commonly reported subjective effects.

Is Proviron bad for your liver?

No. Mesterolone uses 1-alpha-methylation, not the 17-alpha-alkylation that causes hepatotoxicity in oral steroids like oxymetholone and stanozolol. The Bayer SmPC lists no hepatic adverse reactions. Liver enzyme monitoring on Proviron is good practice for completeness but is not expected to show elevations attributable to mesterolone at any standard dose.

Does Proviron cause anxiety?

Mesterolone itself has documented antidepressant properties. Anxiety reports on forums typically result from the androgen-to-oestrogen ratio shifting too far toward the androgenic side, particularly when Proviron is combined with an aromatase inhibitor. The solution is reducing the AI dose or the Proviron dose, not discontinuing all treatment. This is an indirect ratio effect, not a direct pharmacological side effect of mesterolone.

Will Proviron raise my PSA?

All androgens can stimulate prostatic tissue and potentially elevate PSA. Mesterolone’s contribution is limited by its low systemic bioavailability (3%) and the fact that it cannot be further amplified by 5-alpha-reductase in the prostate. PSA should be tested at baseline and at 12-week intervals during use. Any reading above 4.0 ng/mL or a significant increase from baseline warrants medical evaluation.

Are Proviron side effects worse at higher doses?

Yes, all androgenic side effects are dose-dependent. Hair shedding, acne, and prostatic stimulation increase with dose. However, the overall side effect profile remains mild even at 100mg daily compared to other oral steroids, because mesterolone lacks the hepatotoxicity, haematological effects, and severe lipid disturbances associated with 17-alpha-alkylated compounds. The diminishing returns in benefit above 50 to 75mg daily mean that most users achieve optimal risk-to-reward at moderate rather than maximum doses.